CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Cash Flow-to-Debt Ratio
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Cash Flow-to-Debt Ratio of -1.41x as of December 2025, meaning its operating cash flow of $-1.59 Million could theoretically repay -1% of its total liabilities ($1.13 Million) in one year. See CytoMed Therapeutics Limited Ordinary Sh current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CytoMed Therapeutics Limited Ordinary Shares Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. Also explore net asset growth rate of CytoMed Therapeutics Limited Ordinary Sh to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Year-by-year debt coverage analysis for CytoMed Therapeutics Limited Ordinary Shares. For market capitalisation and broader financial context, see GDTC company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.27x | $-3.70 Million | $1.13 Million | ▼ -44.6% |
| 2024 | -2.26x | $-1.69 Million | $749.76K | ▲ +25.6% |
| 2023 | -3.04x | $-2.59 Million | $852.28K | ▼ -853.2% |
| 2022 | -0.32x | $-1.10 Million | $3.46 Million | ▲ +35.0% |
| 2021 | -0.49x | $-1.27 Million | $2.59 Million | ▼ -79.2% |
| 2020 | -0.27x | $-692.31K | $2.53 Million | ▲ +56.9% |
| 2019 | -0.64x | $-471.85K | $742.31K | — |